Cattaneo 2005.

Methods	Design: parallel RCT Duration: not reported Follow up: 12 months
Participants	Setting: single centre Country: Italy Primary kidney transplant recipients Number (group 1/group 2): 21 (11/10) Mean age ± SD (years): group 1 (47.5 ± 16.0); group 2 (42.3 ± 13.2) Sex (M/F): group 1 (7/4); group 2 (5/5) Exclusions: unclear
Interventions	Treatment group 1 SRL: 4 mg and then adjusted to level 5 to 10 ng/mL Treatment group 2 CSA: 1 to 2 mg/kg/d and adjusted to initial level 120 to 220 ng/mL; maintenance 70 to 120 ng/mL Co‐interventions MMF: 1g/d Alemtuzumab: 30 mg MP: 200 mg IV intraoperatively Prednisolone: 250 mg on day 1, 125 mg on day 2
Outcomes	Death (all causes) Graft loss censored for death Graft loss or death with functioning graft Acute rejection CrCl Infection CMV Biochemical adverse effect Surgical adverse effect Cosmetic/lifestyle adverse effect
Notes	Comparison: TORI versus CNI
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "They were allocated to one of the following two study groups according to a randomization design"
Allocation concealment (selection bias)	Unclear risk	Quote: "They were allocated to one of the following two study groups according to a randomization design"
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary outcome was MPA levels & these unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear whether all patients randomised were included in analyses
Selective reporting (reporting bias)	High risk	Only GFR and SCr reported
Other bias	Unclear risk	No report on funding